[Featured Stock] Neofect and Ybrain Rise on News of Completion of Phase 3 Clinical Trial for Depression Treatment

[Asia Economy Reporter Hyunseok Yoo] Neofect is showing strong performance. It appears that the news of its affiliate Ybrain completing Phase 3 clinical trials for the indication of monotherapy for depression has had an impact.

As of 9:18 AM on the 28th, Neofect was trading at 5,570 KRW, up 14.49% (705 KRW) compared to the previous trading day.

Ybrain announced on the 25th that it had successfully completed Phase 3 clinical trials for the indication of monotherapy for depression. The trial evaluated the efficacy and safety of TDCS (transcranial direct current stimulation) treatment to improve depressive symptoms in 65 patients diagnosed with mild to moderate major depressive disorder.

Patients used the electronic medicine for 30 minutes daily over six weeks. More than 50% of the patients with major depressive disorder showed improvement in depressive symptoms and recovered to the normal range. Not only was efficacy confirmed in the depression scale, which is the clinical evaluation index, but symptom improvement was also observed in the anxiety scale.

Based on the significant results of this clinical trial, Ybrain plans to apply for marketing approval and integrated review for new medical technology evaluation in October. Recently, the international guidelines in this field announced the evidence level for monotherapy of depression as A (definite efficacy), raising expectations that the possibility of new medical technology registration will also greatly increase.